GlassScriptPhysician profile
Amy L Edwards
NPI 1497764260
$5,234.95
in general payments reported to CMS, 2019-2025
28 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,037 · 2022: $767 · 2023: $642 · 2024: $1,663 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,431.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.53 | 2021-2025 | |
| Abiomed | $713.47 | 2023-2024 | Impella |
| Sun Pharmaceutical Industries INC. | $683.77 | 2021-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $481.38 | 2021-2025 | Libtayo, Dupixent |
| Janssen Biotech, INC. | $377.33 | 2021-2025 | Tremfya |
| Leo Pharma INC. | $365.17 | 2023-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $353.24 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Prugen, INC. Pharmaceuticals | $245.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $149.33 | 2021-2023 | |
| Pfizer INC. | $128.45 | 2022-2025 | |
| Almirall LLC | $127.41 | 2021-2025 | Klisyri |
| Ucb, INC. | $110.56 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $71.86 | 2025 | Nemluvio |
| Amgen INC. | $64.80 | 2022-2024 | Otezla |
| Genentech USA, INC. | $55.33 | 2021-2024 | Erivedge |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $54.42 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $44.21 | 2021-2022 | |
| Kyowa Kirin, INC. | $33.26 | 2022-2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.67 | 2025 | Spevigo |
| Fresenius Kabi USA, LLC | $25.26 | 2024 | Idacio |
| Arcutis Biotherapeutics, INC. | $21.04 | 2024 | Zoryve |
| Mayne Pharma Commercial LLC | $20.16 | 2021 | |
| Dermira, INC. | $18.49 | 2021 | |
| Biotronik INC. | $17.88 | 2024 | Orsiro Mission |
| Allergan, INC. | $16.41 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $14.54 | 2023 | Valchlor |
| Botanix Sb INC | $13.83 | 2025 | Sofdra |
| W. L. Gore & Associates, INC. | $13.15 | 2023 | Viabahn Endoprosthesis With Propaten Bioactive Surface |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.